2016 Press Releases

2017 | 2016 | 2015 | 2014 | 2013 | 2012

AMAG Pharmaceuticals Announces Appointment of Brian Kelley to Board of Directors

WALTHAM, Mass., Dec. 21, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that Brian Kelley, former president and chief executive officer of Keurig Green Mountain, Inc. has been elected to AMAG’s board of directors, effective December 20, 2016. Mr. Kelley brings... More > 

AMAG Pharmaceuticals Doubles Support of Prematurity Prevention Research

Grant awards in 2016 support promising research aimed at improving the health of mothers and babies WALTHAM, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the company has awarded $300,000 in grants—an increase of $150,000 from last year—to ... More > 

AMAG Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Total GAAP quarterly revenue increased 50% to $143.8 million, driven by record sales of Makena® Significant growth in operating and net income Next-generation development programs progressing well Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -... More > 

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: Credit Suisse 2016 Healthcare Conference Monday, November 7, 2016 at 3:00 p.m. MT (5:00 p.m. ET) Locat... More > 

AMAG Pharmaceuticals to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, November 3, 2016 at 8:00 a.m. ET

WALTHAM, Mass., Oct. 19, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its third quarter 2016 financial results will be released on Thursday, November 3, 2016 before the U.S. financial markets open. At 8:00 a.m. ET, management will host a conference call an... More > 

AMAG Pharmaceuticals Announces Achievement of Key Milestones in Next Generation Development Programs for Makena® and Feraheme®

Definitive pharmacokinetic and comparative pain studies initiated for Makena subcutaneous auto-injector program Estimated sNDA filing for Feraheme Phase 3 label expansion accelerated to mid-2017 based on rapid pace of trial enrollment WALTHAM, Mass., Oct. 12, 2016 (GLOBE NEWSWIRE) -- AMAG Pha... More > 

AMAG Pharmaceuticals Appoints Tony Casciano as Senior Vice President of Hematology/Oncology Sales and Marketing

WALTHAM, Mass., Sept. 07, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today the appointment of Tony Casciano to senior vice president of sales and marketing for the company’s Hematology and Oncology business.  He will report to Nik Grund, AMAG’s chief commercial off... More > 

AMAG Pharmaceuticals to Present at Upcoming Investor Conference

WALTHAM, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in an analyst-led fireside chat at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 10:30 a.m. EDT. A live audio w... More > 

AMAG Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update

Total GAAP quarterly product and service revenues increased approximately 50% to $127 million Makena® (hydroxyprogesterone caproate injection) and Feraheme® (ferumoxytol) achieve record sales Significant progress on next generation Makena and Feraheme development programs Conference call schedu... More > 

AMAG Pharmaceuticals to Host Conference Call on August 9, 2016 at 8:00 a.m. ET to Discuss Financial Results for the Second Quarter Ended June 30, 2016

WALTHAM, Mass., July 21, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it will report unaudited consolidated financial results for the second quarter ended June 30, 2016 before the U.S. financial markets open on Tuesday, August 9, 2016. The announcement will be ... More > 

AMAG Pharmaceuticals CEO William Heiden Elected to PhRMA Board of Directors

WALTHAM, Mass., July 18, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, chief executive officer (CEO), has been named to the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA). "The focus of our work at ... More > 

AMAG Pharmaceuticals Appoints Mark Stanton as Vice President, Market Access & Corporate Accounts

WALTHAM, Mass., July 12, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Mark Stanton to the newly created position of vice president, market access and corporate accounts. In this role, Mr. Stanton will lead the company’s market access and reim... More > 

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., May 25, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will discuss AMAG’s business and financial outlook, strategy and growth prospects at the following investor conferences taking place in June 2016. Jefferies 2016... More > 

AMAG Pharmaceuticals Announces 2016 Analyst Day

WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), a specialty pharmaceutical company with a diverse portfolio of products in the areas of maternal health, anemia management and cancer supportive care, today announced that it will host an Analyst Day in New ... More > 

AMAG Pharmaceuticals Reports First Quarter 2016 Financial Results

First quarter 2016 non-GAAP product revenue increased 52% to $117.6 million1 Entered into new Makena® partnership with a leading provider of home nursing services Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass., May 03, 2016 (GLOBE NEWSWIRE) --  AMAG Pharmaceuticals, Inc... More > 

AMAG Pharmaceuticals to Participate in the Deutsche Bank 41st Annual Healthcare Conference

WALTHAM, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in an analyst-led fireside chat at the Deutsche Bank 41st Annual Healthcare Conference on Wednesday, May 4, 2016 at 8:40 a.m. ET in Boston.  A live audio ... More > 

AMAG Pharmaceuticals to Host Conference Call on May 3, 2016 at 8:00 a.m. ET to Discuss Financial Results for the First Quarter Ended March 31, 2016

WALTHAM, Mass., April 21, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it will report unaudited consolidated financial results for the first quarter ended March 31, 2016 before the U.S. financial markets open on Tuesday, May 3, 2016. The announcement will be fo... More > 

AMAG Pharmaceuticals Appoints Edward Myles as Chief Financial Officer

WALTHAM, Mass., April 11, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Edward (Ted) Myles as senior vice president, chief financial officer and treasurer of AMAG. In this position, Mr. Myles will assume responsibility for AMAG’s financial and... More > 

AMAG Pharmaceuticals to Participate in 15th Annual Needham Healthcare Conference

WALTHAM, Mass., April 06, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in the 15th Annual Needham Healthcare Conference in New York City. The company is scheduled to present on Wednesday, April 13, 2016 at 12:10 pm ET and will p... More > 

AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena® (hydroxyprogesterone caproate injection)

Company also Announces Expansion of Home Healthcare Support through Makena Care Connection WALTHAM, Mass., April 04, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the new single-dose, preservative-free Makena® is now available for prescribing. Makena is th... More > 

AMAG Pharmaceuticals Announces First Patient Enrolled in Head-to-Head Phase 3 Clinical Trial Evaluating Feraheme® in Adults With Iron Deficiency Anemia

Trial marks the final clinical milestone on the pathway to pursue a broader Feraheme® label WALTHAM, Mass., March 16, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it has enrolled the first patient in the head-to-head, Phase 3 clinical trial evaluating the... More > 

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Feb. 26, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will discuss AMAG’s business and financial outlook, strategy and growth prospects at the following investor conferences taking place in March 2016. Cowen and Comp... More > 

AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena® (hydroxyprogesterone caproate injection)

Company Plans for Full Commercial Launch of Makena Line Extension in Second Quarter of 2016 WALTHAM, Mass., Feb. 23, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s single-dose, preservat... More > 

AMAG Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results

Fourth quarter 2015 non-GAAP revenue up 137% to $120.6 million1 Fourth quarter 2015 non-GAAP adjusted EBITDA increased 322% to $61.3 million1 Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass., Feb. 17, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), a specia... More > 

AMAG Pharmaceuticals to Host Conference Call on February 17, 2016 at 8:00 a.m. ET to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2015

WALTHAM, Mass., Feb. 04, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it will report unaudited consolidated financial results for the fourth quarter and year ended December 31, 2015 before the U.S. financial markets open on Wednesday, February 17, 2016. The ann... More > 

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will discuss AMAG’s business and financial outlook, strategy and growth prospects at the following investor conferences taking place in February 2016. LEERINK P... More > 

AMAG Pharmaceuticals Announces Preliminary 2015 Financial Results and Provides 2016 Financial Guidance

Achieves record 2015 annual Feraheme® and Makena® product sales: Makena grows  approximately 52% over 2014 Two maternal health transactions in 2015 to bolster future revenue growth and sustainability Company guides to approximately $545 million and $270 million in 2016 revenue and adjusted E... More > 

AMAG Pharmaceuticals Announces $60 Million Share Repurchase Program

WALTHAM, Mass., Jan. 06, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that its Board of Directors has approved a share repurchase program under which AMAG may purchase up to $60 million of its common stock. The share repurchase program has no time limit and may... More > 

AMAG Pharmaceuticals, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, AMAG’s chief executive officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2016 at 10:00 a.m. Pacific Time. The session w... More > 

AMAG Pharmaceuticals Appoints Nicholas Grund as Chief Commercial Officer

Key Commercial Leadership Changes to Drive Future Business Growth WALTHAM, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Nicholas (Nik) Grund as executive vice president and chief commercial officer of the company. In this new... More >